International Journal of Hematology

DOI: 10.1007/s12185-013-1479-5 Pages: 361-371

Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies

1. Memorial Sloan-Kettering Cancer Center, Leukemia Service, Department of Medicine

2. Memorial Sloan-Kettering Cancer Center, Center for Cell Engineering, Sloan-Kettering Institute

3. Memorial Sloan-Kettering Cancer Center, Department of Pediatrics

Correspondence to:
Renier Brentjens
Tel: +1-212-6397053
Fax: +1-212-7728441



The genetic modification of autologous T cells with chimeric antigen receptors (CARs) represents a breakthrough for gene engineering as a cancer therapy for hematologic malignancies. By targeting the CD19 antigen, we have demonstrated robust and rapid anti-leukemia activity in patients with heavily pre-treated and chemotherapy-refractory B cell acute lymphoblastic leukemia (B-ALL). We demonstrated rapid induction of deep molecular remissions in adults, which has been recently confirmed in a case report involving a child with B-ALL. In contrast to the results when treating B-ALL, outcomes have been more modest in patients with chronic lymphocytic leukemia (CLL) or other non-hodgkin’s lymphoma (NHL). We review the clinical trial experience targeting B-ALL and CLL and speculate on the possible reasons for the different outcomes and propose potential optimization to CAR T cell therapy when targeting CLL or other indolent NHL. Lastly, we discuss the pre-clinical development and potential for clinical translation for using CAR T cells against multiple myeloma and acute myeloid leukemia. We highlight the potential risks and benefits by targeting these poor outcome hematologic malignancies.

This article is freely available, click here to access the full text/PDF

Share the Knowledge